{
    "organizations": [],
    "uuid": "3a0d978c4dd2a4834af68018ed13226bb9d9b274",
    "author": "",
    "url": "https://www.reuters.com/article/brief-celgene-says-entered-into-settleme/brief-celgene-says-entered-into-settlement-with-actavis-idUSFWN1PL16A",
    "ord_in_thread": 0,
    "title": "BRIEF-Celgene Says Entered Into Settlement With Actavis​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "January 26, 2018 / 10:37 PM / in 20 minutes BRIEF-Celgene Says Entered Into Settlement With Actavis​ Reuters Staff 1 Min Read \nJan 26 (Reuters) - Celgene Corp: \n* CELGENE - ENTERED INTO SETTLEMENT WITH ACTAVIS LLC TO TERMINATE PENDING PATENT LITIGATION, IPR CHALLENGES RELATING TO CERTAIN PATENTS FOR ABRAXANE​ \n* CELGENE - TO GIVE ACTAVIS LICENSE TO PATENTS TO MANUFACTURE, SELL GENERIC PACLITAXEL PROTEIN-BOUND PARTICLES IN U.S. FROM MARCH 31, 2022 Source text - bit.ly/2EcZicz Further company coverage:",
    "published": "2018-01-27T00:35:00.000+02:00",
    "crawled": "2018-01-27T00:54:44.029+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "january",
        "pm",
        "minute",
        "say",
        "entered",
        "settlement",
        "reuters",
        "staff",
        "min",
        "read",
        "jan",
        "reuters",
        "celgene",
        "corp",
        "celgene",
        "entered",
        "settlement",
        "actavis",
        "llc",
        "terminate",
        "pending",
        "patent",
        "litigation",
        "ipr",
        "challenge",
        "relating",
        "certain",
        "patent",
        "celgene",
        "give",
        "actavis",
        "license",
        "patent",
        "manufacture",
        "sell",
        "generic",
        "paclitaxel",
        "particle",
        "march",
        "source",
        "text",
        "company",
        "coverage"
    ]
}